Showing 5571-5580 of 5909 results for "".
- Study Results Show NeurOptics’ NPi-200 Pupillometer Provides Early Warning of Neurological Damagehttps://modernod.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/A new study found that NeurOptics’ NPi-200 Pupillometer, which provides an automated assessment of the pupillary light reflex, may signal an early warning of potential delayed cerebral ischemia and enable preemptive escalation of care. The study was published in the Journal of Neurosurgery
- Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimabhttps://modernod.com/news/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/2476355/Roche and Genentech have initiated two large global phase 3 clinical trials in wet age-related macular degeneration (AMD) investigating the bispecific molecule, faricimab. Faricimab is the first bispecific antibody designed specifically for the treatment of retinal eye diseases that simultaneousl
- 2019 Bressler Prize Awarded to Vladimir Kefalov, PhD, for Outstanding Accomplishments in Vision Science Researchhttps://modernod.com/news/2019-bressler-prize-awarded-to-vladimir-kefalov-phd-for-outstanding-accomplishments-in-vision-science-research/2476357/Lighthouse Guild announced that Vladimir Kefalov, PhD, has been awarded the 2019 Bressler Prize for his outstanding advances in vision science research. Dr. Kefalov is one of the leading retinal scientists in the world. His work has generated new insights into mecha
- Eyecare Services Partners Names New CEO and Adds Two Other Executiveshttps://modernod.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/Eyecare Services Partners (ESP) has appointed George Neal as chief executive officer, effective March 4. Mr. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America, according to a
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Penetrating Keratoplasty Effective for Corneal Complications of Shingleshttps://modernod.com/news/penetrating-keratoplasty-effective-for-corneal-complications-of-shingles/2479592/Even in eyes with preoperative risks, penetrating keratoplasty (PKP) can achieve favorable results for the corneal complications of herpes zoster ophthalmicus (HZO), researchers say, as reported by Reuters. “What we learned is
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel